Best Biopharma Outsourcing Companies in Japan
The 103 best Biopharma Outsourcing companies in Japan in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bacchus Bio innovation.
Japan's Biopharma Outsourcing sector is moving faster than the funding numbers alone suggest, and this directory ranks the best Biopharma Outsourcing companies in Japan by disclosed equity funding and recent momentum. Across 103 tracked companies, total disclosed capital sits at $62M, with Bacchus Bio Innovation leading at $11M, Toregem Biopharma close behind at $10M, and a cluster of earlier-stage names like FerroptoCure ($3M), Proteobridge ($2M), and RevolKa ($2M) filling out the mid-tier. Zero unicorns so far, which honestly tells you something about where Japan's biopharma outsourcing build-out sits on the maturity curve.
The global backdrop gives this directory real urgency. The worldwide biopharma outsourcing market was valued at roughly $28.7B in 2024 and is forecast to reach $112.3B by 2032, a CAGR of about 5.8%, driven by rising drug development costs and surging demand for biologics. Clinical trial outsourcing and operational resilience are the themes heating up right now, and increasing regulatory compliance pressure is pushing sponsors toward specialized local partners who know Japan's approval pathways cold. Investors like Kyoto University Innovation Capital, Beyond Next Ventures, and ANRI are circling this space, and if you're mapping the ecosystem, the funding gaps here are as interesting as the leaders.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Japan
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3h clinical trial 3H Clinical Trial offers health event planning, management IT solutions, healthcare marketing research and… | — | — | 250 | — | WordPressApple iCloud MailMySQL+17 | Top 50M | — | — |
| 2 | A2 Healthcare Full-service CRO based out of Japan | — | — | 1,155 | — | WordPressMySQLPHP+11 | Top 5M | 44 patents Synthesis of PET radiotracer flutemetamol and benzimidazole drugs for acid reflux treatment | — |
| 3 | Alfresa Holdings Corporation Manufacture, import & export and wholesaling of drugs and other healthcare products | — | — | 10,936 | — | BootstrapAmazon ALBAmazon Web Services+9 | Top 5M | — | — |
| 4 | Alfresa Pharma Corporation Contract manufacturer of solids and liquid dosage forms | — | — | — | Koichi Shimada CEO | Apache HTTP ServerCloudflareGoogle Hosted Libraries+4 | Top 50M | 165 patents ADAMTS13-targeted antibodies and related diagnostic analysis devices for hematologic disorders | — |
| 5 | apoplus station Apoplus Station provides CSO and CRO business services focusing on medical well being. | — | — | 790 | — | WordPressApple iCloud MailMicrosoft 365+5 | Top 5M | — | — |
| 6 | ASAJES Ventures Provider of investment and clinical development for late-stage biopharmaceutical drug candidates | — | — | — | Chika Yoshinaga Co-Founder & Managing Partner | — | — | — | — |
| 7 | Ascent Development Services Provider of regulatory and consulting services to biopharma sector | — | — | 23 | — | — | — | — | — |
| 8 | Axcelead Drug Discovery Partners Provider of drug research & consulting services | — | — | 70 | — | WordPressMySQLPHP+28 | Top 5M | — | — |
Top 12 Biopharma Outsourcing companies in Japan
#1
Series A · Chiyoda City, Tokyo · founded 2022$3.1Mraised▾
Provider of ferroptosis drug discovery and development solutions. It is a developer of therapeutic drugs to treat cancer and other diseases.
- Sep 2025Series A$3.1M
- Jun 2023Seed—
#2
Seed · Tokyo, Tokyo · founded 2022 · 7 employees$871.2Kraised▾
Provider of pharmaceuticals development & commercialization services
- Jan 2026Seed$569.7K
- Feb 2024Seed$871.2K
#3
Seed · Koto City, Tokyo · founded 2018 · 12 employees$1.6Mraised▾
Provider of Vivo reactions on protein arrays intended to deliver innovative research approach. The company performs high-precision immune profiling based on the resources and developed technologies established by the national institute of advanced industrial science and technology. enabling researchers to study drug discovery, regenerative medicine, and diagnosis.
- Sep 2025Seed$268.9K
- Jun 2022Seed$1.3M
#4
Series A · Kobe, Hyogo · founded 2020 · 22 employees$11.3Mraised▾
CDMO focused on manufacturing of microorganism based drugs
- Nov 2024Series A—
- Jan 2022Series A—
- Nov 2021Series A—
- Feb 2021Series A$11.3M
#5
Series B · Kyoto, Kyoto · founded 2020 · 5 employees$10.4Mraised▾
Bio firm offering research and development in dental drug development. It provides tooth regeneration medicine, treatment, and dental regenerative therapy.
- Aug 2024Series B$10.4M
#6
Series A · Chuo City, Tokyo · founded 2021 · 23 employees$1.7Mraised▾
Provider of AI development services for biopharma sector
- May 2025Series A$1.4M
- Aug 2024Series A$1.7M
#7
Series A · Chuo City, Tokyo · founded 2018 · 10 employees$7.5Mraised▾
Provides drug discovery using cell-free membrane protein preparation and unnatural amino acid
- Aug 2024Series A$4.8M
- Aug 2021Seed$2.7M
#8
Seed · Nishi, Saitama-ken · founded 2019$752.1Kraised▾
Provider of cell quality control and manufacturing services
- Jul 2025Conventional Debt—
- Jul 2025Seed$752.1K
#9
Seed · Osaka, Osaka · founded 2024$120Kraised▾
Developer of an AI platform streamlining drug discovery and development. The platform integrates machine learning and computational modeling to accelerate therapeutic development. It leverages deep learning and generative models to transform the drug discovery pipeline. The platform supports target identification, molecular design, and preclinical evaluation. It uncovers novel therapeutics with greater speed, precision, and scalability.
- Aug 2025Seed$120K
#10
Seed · Osaka, Osaka · founded 2019 · 4 employees$5.4Mraised▾
Operator of a medical research and development company intended to discover and develop cancer treatment drugs. The company's research uses technology to provide information and realize the future of innovative cancer therapeutic drugs and healthy longevity, enabling clinicians to treat patients without hassle.
- Apr 2023Seed$2.2M
- 2022Seed$868.8K
- 2020Seed$1.4M
- Nov 2019Seed$923.1K
#11
Series A · Katsushika City, Tokyo · founded 2018 · 4 employees$4.6Mraised▾
Developer of phenotypic regenerative medicine platforms designed to overcome intractable diseases by manipulating cells with information. The company's platform performs accurate all-gene expression analysis technology to acquire the state of cells treated with various types of drugs and media as large-scale data to extract information, enabling pharmaceutical companies and research institutes to improve the quality of medicine cells at the whole gene level.
- Jul 2023Series A—
- Mar 2021Series A$4.6M
#12
Series B · Chuo, Tokyo · founded 2012$10Mraised▾
Provider of pharmaceutical quality assurance consulting services
- Feb 2016Series B$10M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.